10-Q: Kairos Pharma Reports Wider Losses, Secures Funding

Kairos Pharma, a clinical-stage biopharmaceutical company, reported significantly increased net losses and cash burn for the first half of 2025, while successfully securing over $3.9 million in new financing.

Summary

• Kairos Pharma, Ltd. incurred a net loss of $2,684,000 for the six months ended June 30, 2025, a substantial increase from $576,000 for the same period in 2024.
• Basic and diluted loss per common share increased to $0.16 for the six months ended June 30, 2025, compared to $0.05 in the prior year period.
• Research and development expenses rose significantly to $989,000 for the first half of 2025, up from $228,000 in the first half of 2024, primarily due to the Phase 2 prostate cancer trial.
• General and administrative expenses also saw a sharp increase to $1,733,000 for the six months ended June 30, 2025, from $286,000 in the comparable 2024 period, largely driven by vendor advance amortization.
• The company used $1,519,000 in cash from operating activities during the six months ended June 30, 2025, compared to $132,000 used in the same period of 2024.
• Cash and cash equivalents stood at $3,034,000 as of June 30, 2025, an increase from $1,272,000 at December 31, 2024.
• Shareholders' equity increased to $5,997,000 as of June 30, 2025, from $4,776,000 at December 31, 2024.
• The company successfully raised $3,058,000 in net proceeds from a private financing (PIPE Offering) in January 2025 and $223,000 from its Equity Line of Credit (ELOC) during the six months ended June 30, 2025.
• Subsequent to June 30, 2025, an additional $3,693,000 in net proceeds was raised from the ELOC in July 2025, bringing total ELOC proceeds to $3,903,000 to date.
• The company maintains a material weakness in internal controls over financial reporting due to a lack of sufficient review procedures and segregation of duties.

Sentiment

Score: 4

Explanation: The company reported significantly wider losses and increased cash burn, indicating worsening financial performance. However, these negatives are partially offset by successful capital raises that provide liquidity for the next 12 months. The presence of a material weakness in internal controls and the going concern warning are notable concerns for investors.

Positives

• Successfully secured significant financing through a private placement and an Equity Line of Credit, providing $3,058,000 and $3,903,000 (including subsequent events) in net proceeds, respectively.
• Cash and cash equivalents increased to $3,034,000 as of June 30, 2025, from $1,272,000 at December 31, 2024, improving liquidity.
• The company expects current cash reserves to fund operations for at least 12 months from the filing date.
• Advancing product candidates through clinical trials, including Phase 2 for prostate cancer (ENV 105) and Phase 1 for lung cancer (ENV 105) and KROS 201.

Negatives

• Net loss significantly widened to $2,684,000 for the six months ended June 30, 2025, from $576,000 in the prior year period.
• Loss from operations increased substantially to $2,722,000 for the six months ended June 30, 2025, compared to $514,000 in the prior year.
• Cash used in operating activities increased sharply to $1,519,000 for the six months ended June 30, 2025, indicating a higher cash burn rate.
• Basic and diluted loss per common share worsened to $0.16 for the six months ended June 30, 2025, from $0.05 in the prior year, partly due to increased share count.
• The company has not generated any revenue from product sales since inception and expects to incur significant operating losses for the foreseeable future.
• The ability to continue as a going concern is dependent on raising additional capital and achieving profitable operations, with no assurance of future financing availability or satisfactory terms.

Risks

• The company's ability to continue as a going concern is dependent on attaining and maintaining profitable operations in the future, primarily by raising additional capital.
• No assurance can be given that any future financing will be available or, if available, that it will be on terms satisfactory to the company, potentially leading to undue restrictions or substantial dilution.
• The successful development and commercialization of product candidates is highly uncertain due to numerous risks, including timing and progress of clinical development, regulatory approvals, manufacturing, and intellectual property protection.
• The company expects to incur significant and increasing expenses and operating losses for the foreseeable future as it advances product candidates through development and seeks regulatory approval.
• A material weakness exists in internal controls over financial reporting due to a lack of sufficient review procedures and segregation of duties, which could adversely affect the ability to record, process, summarize, and report financial information.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses as it advances product candidates through preclinical and clinical development, seeks regulatory approval, expands its intellectual property portfolio, and operates as a public company. It will require substantial additional funding to support continuing operations and growth strategy, relying on equity and debt financings, and potential collaboration agreements until revenue generation.

Management Comments

• Our operations have focused on organizing and staffing our Company, business planning, raising capital, acquiring and developing our technology, establishing our intellectual property portfolio, identifying potential product candidates, and undertaking preclinical and clinical studies and manufacturing.
• We do not have any products approved for sale and have not generated any revenue from product sales.
• We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development.
• We expect our current cash reserves to fund the Company's operations for at least 12 months from the date of this filing.
• Our ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future, which will primarily be accomplished by raising additional capital.

Industry Context

Kairos Pharma operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector, specifically focusing on oncology with immunotherapy and cell therapy treatments. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. The company's strategy of leveraging molecular insights to target drug resistance and immune suppression aligns with broader industry trends seeking novel approaches to cancer treatment. Its reliance on external financing and licensing agreements is typical for early-stage biotech companies that have not yet commercialized products.

Comparison to Industry Standards

• Kairos Pharma's financial profile, characterized by significant operating losses and no revenue, is typical for an early-stage clinical biopharmaceutical company. Comparable companies at this stage, such as those with product candidates in Phase 1 or Phase 2 trials (e.g., early-stage oncology biotechs like OncoSec Medical, Checkpoint Therapeutics, or smaller private firms), often exhibit similar financial characteristics.
• The increase in R&D expenses from $228,000 to $989,000 for the six months ended June 30, 2025, is consistent with a company advancing its clinical pipeline, particularly with a Phase 2 trial commencing. This level of R&D spend is expected as clinical trials progress.
• The substantial increase in general and administrative expenses, from $286,000 to $1,733,000, is higher than typical for a company of this size, partly attributed to vendor advance amortization and public company costs. While some increase is expected post-IPO, the magnitude warrants scrutiny.
• The successful capital raises, including a $3.5 million PIPE offering and over $3.9 million from an ELOC, demonstrate the company's ability to attract funding, which is crucial for early-stage biotechs. This is a positive sign in an industry where access to capital is paramount, though it comes with significant shareholder dilution.
• The 'going concern' disclosure is common for pre-revenue biopharmaceutical companies, reflecting the inherent risks and capital requirements of drug development. It does not necessarily indicate imminent failure but highlights the ongoing need for financing.

Corporate Governance

Legal Proceedings

• The company is not currently the subject of any material legal proceeding.

Related Party Transactions

• Dr. Ramachandran Murali, Vice President of Research and Development, is a doctor and scientist at Cedars-Sinai Medical Center and an inventor of three patented technologies licensed by Kairos-Cedars.

Stakeholder Impact

• Shareholders face significant dilution from recent and potential future equity financings (PIPE offering, ELOC) due to the company's need for capital.
• Employees and management are impacted by the company's focus on advancing clinical trials and the need for additional personnel, as well as the ongoing financial losses.
• Creditors and investors face risks associated with the company's 'going concern' status and its reliance on future capital raises to fund operations.
• Research partners and vendors (e.g., Prevail Infoworks, PreCheck Health Services, CEO.CA Technologies, Belair Capital Advisors, Cross Current Capital LLC) are actively engaged through various agreements, indicating ongoing operational activity and commitments.

Next Steps

• Continue advancing current and future product candidates through preclinical and clinical development.
• Seek regulatory approval for product candidates.
• Maintain and expand the intellectual property portfolio.
• Hire additional research and development and business personnel.
• Address and remediate the identified material weakness in internal controls over financial reporting.
• Potentially raise additional capital through equity or debt financings, collaborations, strategic alliances, or licensing arrangements.

Key Dates

Recommendation

Kairos Pharma is an early-stage biopharmaceutical company with no revenue and increasing losses, which is typical for its development stage. While the financial results show a significant increase in net loss and cash burn, the company has successfully secured substantial financing through a PIPE offering and an Equity Line of Credit, providing liquidity for at least the next 12 months. This capital infusion is critical for its continued operations and advancement of clinical trials (Phase 1 and Phase 2). The 'going concern' warning is standard for companies at this stage. For a seasoned investor already holding the stock, the successful capital raises mitigate immediate liquidity concerns, justifying a 'hold' as the company continues its high-risk, high-reward drug development path. For new investors, the high risk profile, significant cash burn, and lack of approved products suggest caution, but the recent financing provides a runway for continued progress.

Keywords

Biotechnology, Oncology, Immunotherapy, Cell Therapy, Clinical Trials, SEC Filing, 10-Q, Financial Results, Capital Raise, Equity Line of Credit, PIPE Offering, ENV 105, KROS 201, Prostate Cancer, Lung Cancer, Drug Development, Going Concern, Internal Controls